Search

Your search keyword '"T. Lavin"' showing total 12 results
Start Over Author "T. Lavin" Journal nephrology dialysis transplantation
12 results on '"T. Lavin"'

1. Long-term safety and efficacy of sodium zirconium cyclosilicate for hyperkalaemia in patients with mild/moderate versus severe/end-stage chronic kidney disease: comparative results from an open-label, Phase 3 study

Author

Edgar V. Lerma, Javed Butler, Steven Fishbane, Bruce Spinowitz, June Zhao, David K. Packham, Stephan von Haehling, Peter A. McCullough, Philip T. Lavin, Mikhail Kosiborod, and Simon D. Roger

Subjects
Male, medicine.medical_specialty, estimated glomerular filtration rate, Hyperkalemia, 030232 urology & nephrology, Urology, Phases of clinical research, Renal function, 030204 cardiovascular system & hematology, Severity of Illness Index, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, hyperkalaemia, Clinical Research, sodium zirconium cyclosilicate, Post-hoc analysis, medicine, Humans, Prospective Studies, Renal Insufficiency, Chronic, AcademicSubjects/MED00340, Prospective cohort study, Aged, Transplantation, business.industry, potassium, Silicates, Patiromer, Middle Aged, Prognosis, medicine.disease, 3. Good health, chemistry, Nephrology, Kidney Failure, Chronic, Female, ORIGINAL ARTICLES, medicine.symptom, business, chronic kidney disease, Biomarkers, Kidney disease
Abstract

Background Sodium zirconium cyclosilicate (SZC; formerly ZS-9) is a selective potassium (K+) binder for the treatment of adults with hyperkalaemia. This post hoc analysis of an open-label, single-arm trial (NCT02163499) compared SZC efficacy and safety >12 months among outpatients with hyperkalaemia and Stages 4 and 5 chronic kidney disease (CKD) versus those with Stages 1–3 CKD. Methods Adults with serum K+ ≥5.1 mmol/L (measured by point-of-care i-STAT device) received SZC 10 g three times daily for 24–72 h until normokalaemia (i-STAT K+ 3.5–5.0 mmol/L) was achieved [correction phase (CP)], followed by once daily SZC 5 g for ≤12 months [maintenance phase (MP)]. Here, patients were stratified by baseline estimated glomerular filtration rate (eGFR, Graphical Abstract

Published
2020
Full Text
View/download PDF

2. P0189SODIUM ZIRCONIUM CYCLOSILICATE CORRECTS HYPERKALAEMIA WITHIN 72 HOURS AMONG OUTPATIENTS WITH SEVERE HYPERKALAEMIA (BASELINE SERUM POTASSIUM ≥6 MMOL/L) REGARDLESS OF RENAL FUNCTION LEVEL OR RAASI USE: POST HOC SUBGROUP ANALYSIS OF A PHASE 3 TRIAL

Author

June Zhao, Edgar V. Lerma, Steven Fishbane, Simon D. Roger, Bhupinder Singh, Pablo E. Pergola, Bruce Spinowitz, Julian G. Martins, Philip T. Lavin, Mikhail Kosiborod, and David K. Packham

Subjects
Transplantation, medicine.medical_specialty, Intention-to-treat analysis, Hyperkalemia, Nausea, business.industry, Peripheral edema, Renal function, Subgroup analysis, Hypokalemia, Nephrology, Internal medicine, medicine, Cardiology, medicine.symptom, Adverse effect, business
Abstract

Background and Aims Most patients with severe hyperkalaemia are treated in hospital settings and are often receiving renin–angiotensin–aldosterone system inhibitors (RAASi) and/or have chronic kidney disease. Sodium zirconium cyclosilicate (SZC; formerly ZS-9) is an orally-administered, non-absorbable, inorganic, selective potassium (K+) binder for the treatment of adults with hyperkalaemia. SZC entraps K+ throughout the gastrointestinal tract in exchange for hydrogen and sodium ions and significantly reduces serum K+ within one hour of administration. We report time to achievement of normokalaemia by baseline RAASi use and estimated glomerular filtration (eGFR) level from a 12-month Phase 3 sub-study among outpatients with baseline serum K+ ≥6 mmol/L undergoing acute treatment up to 72 hours. Method This international, multicentre, open-label, single-arm trial among adults with point-of-care (i-STAT) K+ ≥5.1 mmol/L included prespecified efficacy analyses by baseline serum K+ ≥6 mmol/L. During the acute phase (AP), patients received SZC 10 g three times a day from 24 up to 72 hours until normokalaemia (i-STAT K+ 3.5–5 mmol/L) was achieved, whereupon they entered maintenance treatment. In this analysis of the AP only, we report time to achievement of normokalemia (serum K+ 3.5–5 mmol/L) using the Kaplan-Meier (KM) method, mean change in serum K+ from baseline at 24 hours and distribution of change during the entire AP, and adverse events (AEs) by baseline RAASi use and eGFR level ( Results Of 749 patients in the intention-to-treat AP population of the main study, 126 (16.8%) had baseline serum K+ ≥6 mmol/L, and the vast majority of these patients had achieved normokalaemia by 72 hours (KM estimated proportions 98.6% and 96.1% in the serum K+ Among patients with baseline serum K+ ≥6 mmol/L not on RAASi with an eGFR ≥30 mL/min/173m2 (no RAASi/eGFR ≥30), KM estimated median time to normokalemia was fastest, 22.5 hours (95% Confidence Interval [CI]: 22.0, 68.3), followed by patients on RAASi with an eGFR ≥30 mL/min/173m2 (RAASi/eGFR ≥30), 23.5 hours (95% CI: 22.6, 46.1), followed by patients not on RAASi with an eGFR Median/range/mean change serum K+ values at 24 hours were 4.9/4.3-6/−1.22, 5.1/3.8-6.2/−1.26, 5.3/4.7-6/−1.02, and 5.3/4-6.6/−1.00 mmol/L in the no RAASi/eGFR ≥30, RAASi/eGFR ≥30, no RAASi/eGFR No AEs occurred in the no RAASi/eGFR ≥30 group. AEs occurred in 10.3% of patients in the RAASi/eGFR ≥30 group (n=1 each of myopia, nausea, urinary incontinence, and hypertension), 23.1% of patients in the no RAASi/eGFR Conclusion Outpatient treatment with SZC rapidly normalized serum K+ among patients with baseline serum K+ ≥6 mmol/L with few adverse events. Although patients on RAASis and with an eGFR

Published
2020
Full Text
View/download PDF

3. CKD PATHOPHYSIOLOGY AND CLINICAL STUDIES

Author

Paola Achilli, Francesco Marino, Ioannis Karatzas, Steven Fishbane, Alessandro Domenico Quercia, Yu Du, Richard R. Furman, Katarzyna Maresz, Jack F.M. Wetzels, Gerard A. Rongen, Hyun Yul Rhew, Ogo Egbuna, Mariano Rodriguez, Leena Patel, Kiyoto Koibuchi, Anna-Ewa O Kulik, M Weiswasser, Ken Sakai, Antoine Bouquegneau, Myles Wolf, Ilona Kurnatowska, Chantal Loirat, Alberto Ortiz, Stéphane Poitevin, Tilo Hanowski, Elvira Fernández, Abdul Rashid Qureshi, Françoise Dignat-George, Christophe Legendre, Juan Jesus Carrero, Jeffrey Kaupke, Maurizio Postorino, Pablo E. Pergola, Jaco Botha, Bernhard K Kraemer, Mariusz Kusztal, Camille L. Bedrosian, Ada Braun, Marion Sallée, Katarzyna Jankowska, Marcus E. Kleber, Magdalena Kaczmarska, Georg Schlieper, Yeon Soon Jung, Giuseppe Enia, Rosaria Lupica, Beatriz Martínez Fernández, Taro Hoshino, Peter Boor, Mai Ots-Rosenberg, Maria Pina P Madonna, Ayako Tsuchiya, Cesare Guarena, Usama Elewa, Rika Miura, Graciela E. Delgado, Winfried Maerz, Jacek C Szepietowski, Yoshifumi Ubara, Alan G. Jardine, Thiane Gama-Axelsson, Kaoru Tabei, Vincenzo Cantaluppi, Franco Brescia, Carmine Zoccali, Yao Yu, Akihiro Tsuda, Viatcheslav Rakov, Yasemin G Kurt, Sergio Dellepiane, Mahmut Ilker Yilmaz, Winnie Sohn, Bengt Lindholm, Claudia Carmone, Rabab Mohamed Elbehidy, Ye Na Kim, Bertrand Gondouin, Hark Rim, Larry Greenbaum, Dimitrios Arvanitis, Cristina Masini, Michael Chen, Laetitia Dou, Vincenzo Panichi, Leszek Bieniaszewski, Etienne Cavalier, Federica Genovese, Hikmet Tekce, Giovanni Camussi, Mahmut I Yilmaz, Tacyano Tavares Leite, Stéphane Burtey, Yoshiteru Ohno, Atsushi Aikawa, Peter Braunhofer, Johan Vande Walle, Irina Mititiuc, Olivier Devuyst, Amit Sharma, Stefan Degenhardt, Glenn M. Chertow, Henrik S. Rasmussen, Rannveig Skrunes, Dimitra Nastou, E. Marie Freel, Zbigniew Heleniak, Mahmut Gok, Heike Kielstein, Jesús Egido, Steven Zeig, Patrick B. Mark, David Arroyo, Katarzyna Kunicka, Dimosthenis Vlassopoulos, Paweł Poznański, Bruce Spinowitz, Gian Domenico D Fabbri, Jaap Deinum, Yasmine Draz, Marina Foramitti, K. Lysaja, Marian Klinger, Iris Fuhrmann, Cees Vermeer, A. Villari, Piotr Skrzypczyk, Hubert Scharnagl, Emily P. McQuarrie, Giuseppina Pettinato, Kentaro Tanaka, Bożena Werner, Yasuhisa Sakurai, MałGorzata Sojka, Bolesław Rutkowski, Cric Study Investigators, Song Rong, Adrian Covic, Lisa M. Bernard, Carlo Massimetti, Candice Bezerra Torres De Melo, Davide Medica, Jose M. Valdivielso, Martin Flamant, Markus Ketteler, Morten A. Karsdal, Shay Shemesh, Domenico Santoro, Aoi Nabata, Bhupinder Singh, Jean-Marie Krzesinski, Emmanuelle Vidal-Petiot, Tanja B. Grammer, Sandro Feriozzi, Fabio Malberti, Camilla Tøndel, Tayfun Eyileten, Nikolaos Manolios, K K Larsen, Camillo Porta, Junichi Hoshino, Filippo Benedetto, Jesper N. Bech, Larry A. Greenbaum, Rolfdieter Krause, Dimitrie Siriopol, Catherine Delmas-Frenette, Hideaki Shima, Reginaldo Filho, Katarzyna Kilis-Pstrusinska, Stuart M. Sprague, Akifumi Kushiyama, Kiyonori Ito, Katsunori Saito, Ludomir Stefańczyk, Mari Aoe, Juliette Hadchouel, Juergen Floege, Jürgen Floege, Lara Cavalcante Vaz Cunha, Fernanda Macedo de Oliveira Neves, Honami Mori, Mutlu Saglam, Giovanni Tripepi, Yasemin Gulcan Kurt, Mohamed A El-Shahawy, Ewa Aleksandrowicz, Kristin Jäger, Graziella Caridi, Pierre Delanaye, Moriatsu Miyagi, Desmond Padhi, Mai Sugahara, Kiryong Park, Mait Raag, Renata de Almeida Leitão, Thomas D. Wooldridge, Keiji Hirai, Gianluca Trifirò, Elzbieta Prus-Wojtowicz, Naoki Sawa, Murat Karaman, Alexandre Braga Libório, François Vrtovsnik, Ewa Świerblewska, Yuichirou Ueda, Eiji Ishimura, Yusuf Oguz, Masayo Ogawa, Geoffrey A. Block, Frank H Mose, Ho Sik Shin, Yahsou Delmas, Magdalena Okarska-Napierała, Toshiyuki Aoki, Richard Amdur, Hilmi Umut Unal, Stéphan Troyanov, Tammo Lesch, Amal A Alshal, Edward Chong, Ülle Pechter, Alison Taylor, Katsuhito Mori, Mehmet Kanbay, Akinobu Ochi, Claire Cerini, Naobumi Mise, Susumu Ookawara, Joris H. Robben, Hakki Cetinkaya, Anna Masajtis-Zagajewska, Davide Bolignano, Hilmi Umut Ünal, Mitsuru Ichii, Kensuke Hamada, Naoya Sugiyama, Sebahattin Sari, Gianluca Leonardi, Abdulgaffar Vural, Noémie Jourde-Chiche, Sankar D. Navaneethan, N. Dimkovic, Franziska Knöfel, Marios Papasotiriou, Peter Mt Deen, Fadi Fakhouri, Dimitrios Hadjiyannakos, Erling B. Pedersen, Luigi Biancone, Vassilis Filiopoulos, N. Marx, Masayoshi Mori, Zbigniew Zdrojewski, Giovanni F.M. Strippoli, Yoshio Kaku, Masatomo Chikamori, Angels Betriu, Michele Buemi, Kenmei Takaichi, William T. Smith, Izumi Sugimoto, A. Savvaidis, Daijo Inaguma, Giuseppe Costantino, John F Kincaid, Laura Cosmai, Radosław Pietrzak, Roberto Sabbatini, Michał Nowicki, Stephen R. Ash, Kenichi Ishizawa, Masaaki Inaba, Daniela Leonardis, Piotr Grzelak, Jonas Axelsson, Robert A. Fenton, Massimiliano Migliori, Junichiro Yamamoto, Diana J Leeming, Giovanna Parlongo, Philip T. Lavin, Buket Kin Tekce, Dominic S. Raj, James Cotton, David J. Cohen, Shinya Nakatani, Sangeon Gwoo, Shigeko Hara, Frank Schiepe, Philip Awadalla, Gulali Aktas, Massimo Gai, Maria Roszkowska-Blaim, Neil S. Sheerin, Lei Nan, K: Hess, Haruhisa Miyazawa, Silvia Lucisano, Grahame J Elder, François Madore, Helena Ziółkowska, Cai-Li Wang, Einar Svarstad, Giuseppina Lorenzano, Maria Teresa T Muratore, Alex Yang, Graziella D'Arrigo, Doaa Mohammed Youssef, Janni M Jensen, Marta Gracia, Suetonia C. Palmer, Valeria Cernaro, Borja Quiroga, Anton E. Daul, Francesca Mallamaci, Philippe Brunet, Tomoko Honda, Gerjan Navis, Izumi Yoshida, Domenico Trimboli, and Anjay Rastogi

Subjects
Transplantation, medicine.medical_specialty, Nephrology, business.industry, Medicine, business, Intensive care medicine, Pathophysiology
Published
2014
Full Text
View/download PDF

4. ACID BASE, ION DISORDERS, LITHISASIS

Author

M. A. El-Shahawy, H. S. Rasmussen, P. T. Lavin, A. Yang, D. K. Packham, B. Singh, S. D. Roger, M. Fusaro, L. Dalle Carbonare, A. Dusso, M. V. Arcidiacono, S. Pasho, M. Gallieni, M. S. Ormanji, F. Korkes, R. Meca, L. C. Baia, R. R. Ferraz, I. P. Heilberg, I. Nistor, I. Bararu, M.-C. Apavaloaie, L. Voroneanu, M.-D. Donciu, E. V. Nagler, A. Covic, H.-W. Gil, S.-H. Park, S.-Y. Hong, B. Ponte, H. Alwan, M. Pruijm, D. Ackermann, I. Guessous, G. Ehret, F. Paccaud, M. Mohaupt, A. Pechere-Bertschi, M. Burnier, P.-Y. Martin, M. Bochud, V. Filiopoulos, D. Biblaki, N. Manolios, I. Karatzas, D. Arvanitis, D. Vlassopoulos, A. Altuntas, V. Kidir, S. Inal, S. Diker, N. Cil, H. Orhan, M. T. Sezer, M. Verdelho, N. Rodrigues, F. Ribeiro, W. Y. Qunibi, H. Azar, R. Ossman, M. Flamant, D. Chelala, P. Ria, A. Fabris, C. Branco, G. Gambaro, A. Lupo, J. Hao, L. Qiu, Y. Li, R. Li, X. Li, L. Chen, S. Verdesca, D. Cucchiari, M. Podesta, S. Badalamenti, N. M. H. Veldhuijzen, K. G. F. Gerritsen, W. H. Boer, A. C. Abrahams, F. Mangione, P. Albrizio, V. Sepe, P. Esposito, A. Manini, S. Muciaccia, and A. Dal Canton

Subjects
Transplantation, medicine.medical_specialty, Hyperkalemia, business.industry, Placebo, medicine.disease, Gastroenterology, Tolerability, Nephrology, Diabetes mellitus, Heart failure, Internal medicine, medicine, Risk factor, medicine.symptom, Adverse effect, business, Kidney disease
Abstract

Introduction and Aims: Hyperkalaemia is a risk factor for mortality in patients with cardiovascular disease and chronic kidney disease (CKD) (Goyal, 2012; Torlen, 2012) and limits use of renin-angiotensin-aldosterone system inhibitors (RAASi) in these patients. Sodium (or calcium) polystyrene sulfonate (SPS/CPS) has uncertain efficacy and has been associated with substantial adverse events, as well as poor gastrointestinal tolerability, and hence is suboptimal for acute use and unsuitable for chronic use (Harel, 2013; Sterns, 2010). Therefore, there is a need for a hyperkalaemia treatment that rapidly reduces serum potassium (K+) and is safe and well tolerated in these patients. ZS-9, a nonabsorbed cation exchanger designed to specifically entrap excess K +, significantly reduced K+ vs placebo over 48 hr with excellent tolerability in patients with CKD (Ash, 2013). We report acute-phase efficacy in a Phase 3 trial of ZS-9 in patients with hyperkalemia. Methods: Patients (N=753) with serum K+ 5.0-6.5 mmol/L were randomised (1:1:1:1:1) to ZS-9 (1.25g, 2.5g, 5g or 10g) or placebo given three times daily (TID) with meals for 48 hr (acute phase), after which those with K+ ≤4.9 mmol/L (n=542) were re-randomised to ZS-9 or placebo once daily for Day 3-15. Serum K+ was measured at baseline and at predefined intervals, including 1, 4, 24, and 48 hr after the first dose. The acute-phase primary efficacy endpoint was the rate of K+ change over the first 48 hr, using longitudinal modeling to account for all post-baseline data. Results:Mean K+ at baseline was 5.3 mmol/L. Substantial percentages of patients had CKD (60%), a history of heart failure (40%), or diabetes (60%) or were on RAASi therapy (67%). ZS-9 demonstrated significant dose-dependent reductions in K+; the acute-phase primary efficacy endpoint was met for ZS-9 2.5g (p=0.0009), 5g (p

Published
2014
Full Text
View/download PDF

5. SP421SODIUM ZIRCONIUM CYCLOSILICATE FOR HYPERKALAEMIA IN PATIENTS WITH DIABETES MELLITUS: RETROSPECTIVE ANALYSIS OF A 12 MONTH OPEN LABEL, PHASE 3 STUDY

Author

Edgar V. Lerma, Peter A. McCullough, Javed Butler, Scott Adler, Stephan von Haehling, Bruce Spinowitz, David K. Packham, Simon D. Roger, Philip T. Lavin, Mikhail Kosiborod, and Steven Fishbane

Subjects
Transplantation, medicine.medical_specialty, Zirconium, Hyperkalemia, business.industry, 030232 urology & nephrology, Phases of clinical research, chemistry.chemical_element, medicine.disease, 03 medical and health sciences, 0302 clinical medicine, chemistry, Nephrology, Internal medicine, Diabetes mellitus, medicine, Retrospective analysis, In patient, Open label, medicine.symptom, business, Sodium zirconium cyclosilicate, 030217 neurology & neurosurgery
Published
2018
Full Text
View/download PDF

6. FP071SAFETY AND EFFICACY OF SODIUM ZIRCONIUM CYCLOSILICATE FOR LONG-TERM TREATMENT OF HYPERKALAEMIA IN PATIENTS WITH CHRONIC KIDNEY DISEASE: RESULTS FROM AN OPEN-LABEL, PHASE 3 STUDY

Author

Edgar V. Lerma, Steven Fishbane, Javed Butler, Philip T. Lavin, Bruce Spinowitz, Mikhail Kosiborod, Peter A. McCullough, Simon D. Roger, Stephan von Haehling, David K. Packham, and Scott Adler

Subjects
Transplantation, medicine.medical_specialty, Long term treatment, business.industry, Urology, Phases of clinical research, medicine.disease, 030226 pharmacology & pharmacy, 03 medical and health sciences, 0302 clinical medicine, Nephrology, medicine, In patient, Open label, business, Sodium zirconium cyclosilicate, 030217 neurology & neurosurgery, Kidney disease
Published
2018
Full Text
View/download PDF

7. FP003ACHIEVEMENT AND MAINTENANCE OF NORMOKALAEMIA IN PATIENTS WITH NON-DIALYSIS STAGE 5 CHRONIC KIDNEY DISEASE

Author

Henrik S. Rasmussen, David C. Wheeler, David K. Packham, Alex Yang, Michel Jadoul, Angel L.M. de Francisco, Lakhmir S. Chawla, Bhupinder Singh, Philip T. Lavin, and Harmonize Study

Subjects
Transplantation, medicine.medical_specialty, Stage 5 chronic kidney disease, Nephrology, business.industry, Internal medicine, medicine.medical_treatment, medicine, In patient, business, Dialysis, Surgery
Published
2015
Full Text
View/download PDF

8. FP007EFFICIENCY OF SODIUM ZIRCONIUM CYCLOSILICATE (ZS-9) INCREASES WITH SEVERITY OF HYPERKALAEMIA: SUBGROUP ANALYSIS OF PATIENTS STRATIFIED BY BASELINE POTASSIUM IN THE PHASE 3 HARMONIZE STUDY

Author

Bruce Spinowitz, Philip T. Lavin, Henrik S. Rasmussen, Johannes F.E. Mann, and Alex Yang

Subjects
Transplantation, medicine.medical_specialty, Hyperkalemia, business.industry, Potassium, Urology, chemistry.chemical_element, Subgroup analysis, chemistry, Nephrology, Phase (matter), medicine, medicine.symptom, business, Sodium zirconium cyclosilicate
Published
2015
Full Text
View/download PDF

9. FO012NORMALIZATION OF SERUM BICARBONATE WITH SODIUM ZIRCONIUM CYCLOSILICATE (ZS-9) IN THE PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED HARMONIZE STUDY

Author

Philip T. Lavin, Johannes F.E. Mann, Bruce Spinowitz, Bhupinder Singh, Alex Yang, Angel L.M. de Francisco, Michel Jadoul, and Henrik S. Rasmussen

Subjects
Double blind, Transplantation, Chromatography, Nephrology, business.industry, Phase (matter), Medicine, Placebo, business, Sodium zirconium cyclosilicate, Serum bicarbonate
Published
2015
Full Text
View/download PDF

10. FP001EFFECT OF SODIUM ZIRCONIUM CYCLOSILICATE (ZS-9) ON URINARY POTASSIUM AND SODIUM: AN ANALYSIS OF THE PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED HARMONIZE STUDY

Author

Philip T. Lavin, Johannes F.E. Mann, Simon D. Roger, Alex Yang, Henrik S. Rasmussen, Bhupinder Singh, Harmonize Study, and Michel Jadoul

Subjects
Transplantation, Urinary potassium, business.industry, Urinary system, Sodium, Potassium, Mineralogy, chemistry.chemical_element, Placebo, Double blind, chemistry, Nephrology, Phase (matter), Medicine, business, Sodium zirconium cyclosilicate, Nuclear chemistry
Published
2015
Full Text
View/download PDF

11. FP008ACHIEVEMENT OF NORMAL SERUM POTASSIUM WITH SODIUM ZIRCONIUM CYCLOSILICATE (ZS-9) IN A SUBGROUP OF PATIENTS WITH STAGE 4/5 CHRONIC KIDNEY DISEASE AND BASELINE POTASSIUM ≥5.5 MMOL/L FROM THE PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED HARMONIZE STUDY

Author

Angel L.M. de Francisco, Henrik S. Rasmussen, Alex Yang, Wajeh Y. Qunibi, Bhupinder Singh, Simon D. Roger, and Philip T. Lavin

Subjects
Transplantation, medicine.medical_specialty, business.industry, Potassium, chemistry.chemical_element, Normal serum, Placebo, medicine.disease, Gastroenterology, Double blind, Endocrinology, chemistry, Nephrology, Internal medicine, Mole, medicine, Stage (cooking), business, Sodium zirconium cyclosilicate, Kidney disease
Published
2015
Full Text
View/download PDF

12. FP010MAINTENANCE OF NORMAL SERUM POTASSIUM WITH SODIUM ZIRCONIUM CYCLOSILICATE (ZS-9) IN SUBGROUP OF PATIENTS WITH HISTORY OF CHRONIC KIDNEY DISEASE AND ON RAAS INHIBITORS FROM THE PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED HARMONIZE STUDY

Author

Bhupinder Singh, David K. Packham, Henrik S. Rasmussen, Alex Yang, Philip T. Lavin, and Simon D. Roger

Subjects
Transplantation, medicine.medical_specialty, business.industry, Potassium, chemistry.chemical_element, Pharmacology, Normal serum, medicine.disease, Placebo, Double blind, Endocrinology, chemistry, Nephrology, Internal medicine, Renin–angiotensin system, medicine, business, Sodium zirconium cyclosilicate, Serum potassium level, Kidney disease
Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results